Cite Jump to ExpandCollapse ArticleJuly 21, 2026 Dual-pH LC–ESI–MS/MS Expands Peptide Detectability via Wrong-Way-Round Ionization Click to copy article linkArticle link copied! Ola Svahn* Ola Svahn School of Education and Environment, Division of Natural Sciences, Kristianstad University, SE-291 88 Kristianstad, Sweden *Email: [email protected] Jonatan Svahn Jonatan Svahn Department of Computer Science, Lund University, SE-221 00 Lund, Sweden Jan Astermark Jan Astermark Department of...
Jan Astermark
Sweden
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jan Astermark
florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia
1 Introduction Haemophilia is a rare X-linked congenital bleeding disorder characterised by a deficiency of coagulation factor VIII (FVIII) in haemophilia A (HA) or factor IX (FIX) in haemophilia B (HB) as a result of pathogenic variants in the F8 and F9 clotting factor genes [1]. Core to the natural course of haemophilia are bleeds including joint haemorrhage, which may lead to arthropathy and disability.
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study
Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study
1 Introduction Historically, physical activity (PA) has been associated with a perceived increased risk of bleeding in people with haemophilia A (PwHA), with early recommendations suggesting that PwHA should restrict their PA [1]. With the advent of therapies that exert effective bleeding control, there is a need to look beyond bleeding rates as a measure of disease control, to quality of life (QoL), muscle strength, and PA outcomes [2].
Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study
1 Introduction Historically, physical activity (PA) has been associated with a perceived increased risk of bleeding in people with haemophilia A (PwHA), with early recommendations suggesting that PwHA should restrict their PA [1]. With the advent of therapies that exert effective bleeding control, there is a need to look beyond bleeding rates as a measure of disease control, to quality of life (QoL), muscle strength, and PA outcomes [2].
Evaluation of One‐Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy
1 Introduction Etranacogene dezaparvovec (HEMGENIX, AMT-061) was the first gene therapy to receive full US Food and Drug Administration approval for haemophilia B (HB). In addition, etranacogene dezaparvovec has received conditional approval from the European Medicines Agency and has been recommended for use in the National Health Service by the UK National Institute of Health and Care Excellence for the treatment of HB [1-3].
Entering a New Era in Protection in Haemophilia A
Welcome and Introduction Jan Astermark Despite regular and early prophylactic treatment, PwHA at all ages still experience bleeds that impact their daily lives.
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries-Comparisons to Matched Controls
1 Introduction Comorbidities directly linked to haemophilia and its treatment, including haemophilic arthropathy and blood borne infections, have been thoroughly studied and described in the literature [1-7].
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
1 Introduction The 2024 International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia A and B (ISTH Guideline) [1], the 2016 NBDF-McMaster Guideline on Care Models for Haemophilia Management (Care Models Guideline) [2], and the two ASH ISTH NBDF WFH 2021 guidelines on the diagnosis and management of von Willebrand disease (VWD Guidelines) [3, 4] utilized GRADE (Grading of Recommendations Assessment, Development and Evaluation)...
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
1 Introduction Clinical practice guidelines are the cornerstone of optimal patient care using evidence-based recommendations, where possible, which facilitate access to quality treatment. Creating such guidelines, which can be relevant for the diverse healthcare settings around the world for haemophilia care, is challenging. From the historical perspective, the first attempt came through the initiative of the World Federation of Haemophilia (WFH) in 2005.
Health‐related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
1 INTRODUCTION Haemophilic arthropathy may affect health-related quality of life (HRQoL), commonly expressed as health utility.1-4 In severe haemophilia, primary prophylaxis has demonstrated favourable results in preventing arthropathy and is considered the standard of care.5, 6 Accordingly, long-term prophylaxis has been associated with higher health utility than episodic therapy.7, 8 In Sweden, the earlier the prophylaxis was started, the better was the HRQoL.9 Furthermore, prophylaxis has...
Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
Abstract Introduction Head-to-head evaluation of valoctocogene roxaparvovec, the first gene therapy approved for haemophilia A, with emicizumab is not available. Therefore, phase 3 trial data were indirectly compared. Aim To compare bleeding rates in trials evaluating 6 × 1013 vg/kg valoctocogene roxaparvovec (GENEr8-1; NCT03370913), 1.5 mg/kg emicizumab dosed every week (HAVEN 3; NCT02847637), and FVIII prophylaxis (270–902) in participants with severe haemophilia A (FVIII ≤1 IU/dL).
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A
Abstract Introduction The timing of prophylaxis and F8 genotype can impact treatment outcomes in adults with severe haemophilia A (HA). Aim To investigate how F8 genotype, timing, and type of prophylaxis influence arthropathy, bleeding rates, factor consumption and health-related quality of life (HRQoL). Methods Thirty-eight patients with severe HA were enrolled. Bleeding events were recorded retrospectively during median 12.5 months. F8 gene variants were classified as null or non-null.
Koagulationsfaktor XIII - inte bara ett kongenitalt blödningsproblem
Kongenital faktor XIII-brist är en ovanlig blödningsrubbning som oftast diagnostiseras i nyföddhetsperioden och medför en livslång risk för blödningar. Den behandlas med faktor XIII-koncentrat. Autoantikroppsbildning mot FXIII är mer sällsynt. Dessa tillstånd kan misstänkas vid normal APTT och PK(INR) hos en blödande patient. Autoantikroppar kan misstänkas vid nytillkommen blödningsbenägenhet hos vuxna patienter.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jan
Contact Jan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack